DE69725293T2 - N-(2 oxoacetyl oder sulphonyl)-pyrrolidine/piperidine-2-carbonsäurederivate mit verbesserter multi-drug resistenz aktivität - Google Patents

N-(2 oxoacetyl oder sulphonyl)-pyrrolidine/piperidine-2-carbonsäurederivate mit verbesserter multi-drug resistenz aktivität Download PDF

Info

Publication number
DE69725293T2
DE69725293T2 DE69725293T DE69725293T DE69725293T2 DE 69725293 T2 DE69725293 T2 DE 69725293T2 DE 69725293 T DE69725293 T DE 69725293T DE 69725293 T DE69725293 T DE 69725293T DE 69725293 T2 DE69725293 T2 DE 69725293T2
Authority
DE
Germany
Prior art keywords
branched
chain
alkyl
straight
radical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69725293T
Other languages
German (de)
English (en)
Other versions
DE69725293D1 (de
Inventor
M. David ARMISTEAD
O. Jeffrey SAUNDERS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69725293D1 publication Critical patent/DE69725293D1/de
Publication of DE69725293T2 publication Critical patent/DE69725293T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
DE69725293T 1996-03-29 1997-03-24 N-(2 oxoacetyl oder sulphonyl)-pyrrolidine/piperidine-2-carbonsäurederivate mit verbesserter multi-drug resistenz aktivität Expired - Lifetime DE69725293T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US626259 1996-03-29
US08/626,259 US5717092A (en) 1996-03-29 1996-03-29 Compounds with improved multi-drug resistance activity
PCT/US1997/004916 WO1997036869A1 (en) 1996-03-29 1997-03-24 N-(2 oxoacetyl or sulphonyl)-pyrrolidine/piperidine-2-carboxylic acid derivatives with improved multi-drug resistance activity

Publications (2)

Publication Number Publication Date
DE69725293D1 DE69725293D1 (de) 2003-11-06
DE69725293T2 true DE69725293T2 (de) 2004-07-15

Family

ID=24509627

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69725293T Expired - Lifetime DE69725293T2 (de) 1996-03-29 1997-03-24 N-(2 oxoacetyl oder sulphonyl)-pyrrolidine/piperidine-2-carbonsäurederivate mit verbesserter multi-drug resistenz aktivität

Country Status (11)

Country Link
US (2) US5717092A (enExample)
EP (1) EP0891331B1 (enExample)
JP (1) JP4759762B2 (enExample)
AT (1) ATE251140T1 (enExample)
AU (1) AU2346597A (enExample)
CA (1) CA2249369A1 (enExample)
DE (1) DE69725293T2 (enExample)
DK (1) DK0891331T3 (enExample)
ES (1) ES2208890T3 (enExample)
PT (1) PT891331E (enExample)
WO (1) WO1997036869A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150527A (en) * 1994-08-18 2000-11-21 Ariad Pharmaceuticals, Inc. Synthetic multimerizing agents
US6133456A (en) * 1994-08-18 2000-10-17 Ariad Gene Therapeutics, Inc. Synthetic multimerizing agents
US20030036654A1 (en) * 1994-08-18 2003-02-20 Holt Dennis A. Synthetic multimerizing agents
US5795877A (en) * 1996-12-31 1998-08-18 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US5801187A (en) 1996-09-25 1998-09-01 Gpi-Nil Holdings, Inc. Heterocyclic esters and amides
US6218424B1 (en) * 1996-09-25 2001-04-17 Gpi Nil Holdings, Inc. Heterocyclic ketone and thioester compounds and uses
US5786378A (en) * 1996-09-25 1998-07-28 Gpi Nil Holdings, Inc. Heterocyclic thioesters
JP2002515051A (ja) * 1996-12-31 2002-05-21 ジーピーアイ エヌアイエル ホールディングス インコーポレイテッド ヘテロ環式チオエステルのｎ−結合スルホンアミド
US5935989A (en) 1996-12-31 1999-08-10 Gpi Nil Holdings Inc. N-linked ureas and carbamates of heterocyclic thioesters
EP0959882A4 (en) * 1996-12-31 2001-12-05 N-LINKED UREAS AND CARBAMATES OF HETEROCYCLIC THIOESTERS
US5874449A (en) * 1996-12-31 1999-02-23 Gpi Nil Holdings, Inc. N-linked sulfonamides of heterocyclic thioesters
US6242468B1 (en) 1997-02-27 2001-06-05 Jia-He Li Carbamate and urea compositions and neurotrophic uses
US5846979A (en) * 1997-02-28 1998-12-08 Gpi Nil Holdings, Inc. N-oxides of heterocyclic esters, amides, thioesters, and ketones
US5945441A (en) 1997-06-04 1999-08-31 Gpi Nil Holdings, Inc. Pyrrolidine carboxylate hair revitalizing agents
US20010049381A1 (en) 1997-06-04 2001-12-06 Gpl Nil Holdings, Inc., Pyrrolidine derivative hair growth compositions and uses
US6852496B1 (en) * 1997-08-12 2005-02-08 Oregon Health And Science University Methods of screening for agents that promote nerve cell growth
EP1069897A1 (en) * 1998-04-08 2001-01-24 Eli Lilly And Company Methods for inhibiting mrp1
TR200002851T2 (tr) * 1998-04-08 2000-12-21 Eli Lilly And Company MRP1'i inhibe etmek için yöntemler.
US6410041B1 (en) 1998-04-28 2002-06-25 Trustees Of Tufts College Culturing cells in presence of amphipathic weak bases and/or cations and multiple drug resistance inhibitor containing reserpine
US20020131972A1 (en) * 1998-05-21 2002-09-19 Daniel Sem Multi-partite ligands and methods of identifying and using same
CA2333997A1 (en) 1998-06-02 1999-12-09 Bristol-Myers Squibb Company Neurotrophic difluoroamide agents
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
KR20010052503A (ko) 1998-06-03 2001-06-25 다니엘 피. 맥컬럼 Ｎ-헤테로사이클릭 카복실산 또는 카복실산 등입체의ｎ-결합된 설폰아미드
EP1117635A1 (en) * 1998-09-30 2001-07-25 The Procter & Gamble Company 2-substituted ketoamides
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6228872B1 (en) 1998-11-12 2001-05-08 Bristol-Myers Squibb Company Neurotrophic diamide and carbamate agents
US6358531B1 (en) * 1999-02-01 2002-03-19 The Curators Of The University Of Missouri Method for preparing porous shells or gels from glass particles
AU6387500A (en) * 1999-08-05 2001-03-05 Procter & Gamble Company, The Multivalent exocyclic diketo compounds
WO2001027116A2 (en) * 1999-10-07 2001-04-19 Eli Lilly And Company Condensed dihydroquinolinone derivatives for inhibiting mrp1
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
US6417189B1 (en) 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
US6818643B1 (en) 1999-12-08 2004-11-16 Bristol-Myers Squibb Company Neurotrophic bicyclic diamides
MXPA02006134A (es) 1999-12-21 2002-12-13 Guilford Pharm Inc Compuestos derivados de hidantoina, composiciones farmaceuticas y metodos de uso de los mismos.
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6593362B2 (en) 2001-05-21 2003-07-15 Guilford Pharmaceuticals Inc. Non-peptidic cyclophilin binding compounds and their use
US20030203890A1 (en) * 2001-05-29 2003-10-30 Steiner Joseph P. Method for treating nerve injury caused as a result of surgery
US7653490B2 (en) * 2001-09-10 2010-01-26 Triad Liquidating Company LLC Nuclear magnetic resonance assembly of chemical entities
BR0213989A (pt) * 2001-11-07 2005-03-01 Pharmacia Corp Métodos para promover a absorção e acúmulo nuclear de poliamidas em células eucarióticas
US6635892B2 (en) * 2002-01-24 2003-10-21 Pei Electronics, Inc. Compact integrated infrared scene projector
US20030180797A1 (en) * 2002-03-20 2003-09-25 Lin Yu Identification of ligands for a receptor family and related methods
EP1490098B1 (en) * 2002-03-25 2010-03-17 Technologie Biolactis Inc. Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof
WO2005007162A1 (en) * 2003-07-10 2005-01-27 Vertex Pharmaceuticals Incorporated Compounds augmenting the activity of antibacterial agents
CN1281210C (zh) * 2003-11-29 2006-10-25 胡汛 五味子乙素在制备治疗肿瘤药物中的应用
US20060189551A1 (en) * 2004-10-04 2006-08-24 Duke University Combination therapies for fungal pathogens
KR20070090913A (ko) * 2004-12-20 2007-09-06 와이어쓰 라파마이신 유사체 및 신경계, 증식성 및 염증성 장애의치료에서의 이들의 용도
WO2006068905A2 (en) * 2004-12-20 2006-06-29 Wyeth Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
JP5767900B2 (ja) 2011-08-24 2015-08-26 株式会社東芝 水中溶接装置及び方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4920218A (en) * 1988-10-12 1990-04-24 Merck & Co., Inc. Novel hydroxide mediated FK-506 rearrangement process
DE4015255A1 (de) * 1990-05-12 1991-11-14 Hoechst Ag Oxalyl-aminosaeurederivate, verfahren zu ihrer herstellung und ihrer verwendung als arzneimittel zur inhibierung der prolyl-hydroxylase
US5192773A (en) * 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
GB2247456A (en) * 1990-09-03 1992-03-04 Fujisawa Pharmaceutical Co Tetrahydropyrane compounds, a process for their production and a pharmaceutical composition containing the same
HU217621B (hu) * 1991-05-09 2000-03-28 Vertex Pharmaceuticals Inc. Eljárás új glioxaloil-pipekolinsav-észterek, származékaik és az ezeket tartalmazó gyógyszerkészítmények előállítására
US5620971A (en) * 1991-05-09 1997-04-15 Vertex Pharmaceuticals Incorporated Biologically active acylated amino acid derivatives
US5250678A (en) * 1991-05-13 1993-10-05 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
AU2152092A (en) * 1991-06-24 1993-01-25 Erziehungsdirektion Of The Canton Zurich Neurite growth regulatory factors
EP0660959A4 (en) * 1992-09-07 1998-05-06 Mikoh Technology Ltd Diffraction surface data detector.
NZ314207A (en) * 1992-09-28 2000-12-22 Vertex Pharma 1-(2-Oxoacetyl)-piperidine-2-carboxylic acid derivatives as multi drug resistant cancer cell sensitizers
ES2245781T3 (es) * 1994-08-18 2006-01-16 Ariad Gene Therapeutics, Inc. Nuevos agentes de multimerizacion.
US5859031A (en) * 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity

Also Published As

Publication number Publication date
PT891331E (pt) 2004-02-27
CA2249369A1 (en) 1997-10-09
JP4759762B2 (ja) 2011-08-31
AU2346597A (en) 1997-10-22
ES2208890T3 (es) 2004-06-16
DE69725293D1 (de) 2003-11-06
EP0891331A1 (en) 1999-01-20
DK0891331T3 (da) 2004-02-09
US5935954A (en) 1999-08-10
JP2000507578A (ja) 2000-06-20
EP0891331B1 (en) 2003-10-01
ATE251140T1 (de) 2003-10-15
WO1997036869A1 (en) 1997-10-09
US5717092A (en) 1998-02-10

Similar Documents

Publication Publication Date Title
DE69725293T2 (de) N-(2 oxoacetyl oder sulphonyl)-pyrrolidine/piperidine-2-carbonsäurederivate mit verbesserter multi-drug resistenz aktivität
DE69738382T2 (de) Heterozyklische Thioester und Ketone
DE69524400T2 (de) Neue carbamate und harnstoffderivate als modifikatoren der multidrugresistenz
DE69532561T2 (de) Neue Aminosäurederivate mit verbesserter Multi-Drug-Resistenz-Aktivität
DE69127970T2 (de) Immunosuppressive verbindungen
DE69622871T2 (de) Tetralin-verbindungen mit multi-drugresistenz (mdr)-aktivitat
DE69635550T2 (de) Verfahren und mittel zur anregung des neuritwachstums
EP1341764B1 (de) Ortho-substituierte stickstoffhaltige bisarylverbindungen zur verwendung als kalium-kanal-inhibitoren
EP1349846B1 (de) Arylierte furan- und thiophencarbonsaureamide mit kalium kanal blockierender wirkung
DE69428903T2 (de) Substituierte 2-aminotetraline
DE69111619T2 (de) 1,4-benzothiazedinderivat.
DE10059418A1 (de) Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE60210784T2 (de) Orale antidiabetische wirkstoffe
WO2001027109A2 (de) Tert.-butyl-(7-methyl-imidazo[1,2-a]pyridin-3-yl)-amin-derivate
DE19540027A1 (de) Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
EP1073631A1 (de) Neue substituierte amide, deren herstellung und anwendung
DE60306546T2 (de) Entzündungshemmende 3-arylthio-3-thiazolylalkylamine
DE69935331T2 (de) Verfahren und verbindungen zur behandlung der depression
WO1999061423A1 (de) Neue heterocyclische substituierte amide, deren herstellung und anwendung
DE69837564T2 (de) Azaheterozyklische derivate zur behandlung von haarausfall und neurologischer krankheiten
DE10121002A1 (de) Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen
DE10048715A1 (de) Verwendung von Aminosäure zur Behandlung von Schmerz
DE69826881T2 (de) Neue indolcarboxamide, pharmazeutische zusammensetzungen und methoden zur hemmung von calpain
DE69912639T2 (de) N-formyl hydroxylamin derivate als antibakterielle mittel
DE10312073A1 (de) 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxy-pyridin-3yl)-propyl]-benzamid, dessen Verwendung als Medikament sowie dieses enthaltende pharmazeutische Zubereitungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition